Exercise as a lifestyle modification is a frontline therapy for nonalcoholic fatty liver disease
(NAFLD), but how components of exercise attenuate steatosis is unclear. To uncouple the …

Objective The mechanisms underlying non-alcoholic steatohepatitis (NASH) are not
completely elucidated. In the current study we integrated gene expression profiling of liver …

Excess hepatic storage of triglycerides is considered a benign condition, but nonalcoholic
steatohepatitis (NASH) may progress to fibrosis and promote atherosclerosis. Carriers of the …

Background and Aims NAFLD is a lipotoxic disease wherein hepatic steatosis and oxidative
stress are key pathogenic features. However, whether free amino acids (FAAs) are …

The t rans m embrane e mp24 d omain/p24 (TMED) family are essential components of the
vesicular transport machinery. Members of the TMED family serve as cargo receptors …

Hepatic fatty acid elongase-5 (Elovl-5) plays an important role in long chain
monounsaturated and polyunsaturated fatty acid synthesis. Elovl-5 activity is regulated …

Although the exact cause of NAFLD or NASH has not been elucidated, we are now able to
begin to understand the genetic basis for the disease. NAFLD clusters in families, 11 and its …

Currently potential preclinical drugs for the treatment of nonalcoholic steatohepatitis (NASH)
and NASH-related pathopoiesis have failed to achieve expected therapeutic efficacy due to …

BACKGROUND The lack of effective pharmacotherapies for nonalcoholic fatty liver disease
(NAFLD) is mainly attributed to insufficient research on its pathogenesis. The pathogenesis …

Systemic metabolic syndrome significantly increases the risk of morbidity and mortality in
patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis …